Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

NCT02979821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

HER2 Gene Mutation
Adenocarcinoma Lung Stage IV

Interventions

DRUG: Poziotinib

Sponsor

Korean Association for the Study of Targeted Therapy

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]